Transforming growth factor β1 as an inducer of matrix metalloprotease expression and activity in human bone-metastasizing cancer cells

Clinical and Experimental Metastasis

Volumn 17, Issue 1, 1999, Pages 27-34

  Duivenvoorden, Wilhelmina C M ^a   Hirte, Holger W ^a   Singh, Gurmit ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b JURAVINSKI CANCER CENTRE   (Canada)

Author keywords

Bone; Matrix metastasis; Metalloproteinases; TGF 1

Indexed keywords

CIS ACTING ELEMENT; GELATINASE A; GELATINASE B; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA1; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ARTICLE; BONE METASTASIS; BREAST ADENOCARCINOMA; BREAST EPITHELIUM; CANCER CELL CULTURE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INDUCTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; OSTEOSARCOMA; PROMOTER REGION; PROSTATE ADENOCARCINOMA;

ANIMALS; BONE NEOPLASMS; ENZYME INDUCTION; EXTRACELLULAR MATRIX; HUMANS; METALLOENDOPEPTIDASES; MICE; MICE, NUDE; TRANSFORMING GROWTH FACTOR BETA;

EID: 0032983385     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Kanis JA. Bone, cancer: pathophysiology and treatment of metastases. Bone 1995; 17: 101S-5S.
2. Furcht LT, Skubitz APN, Fields GB. Tumor cell invasion, matrix metalloproteinases, and the dogma. Lab Invest 1994; 70: 781-3.
3. Pauli BU, Knudson W. Tumor invasion: a consequence of destructive and compositional matrix alterations. Human Pathol 1988; 19: 628-39.
4. Sanchez-Sweatman, Singh G, Krüger A et al. Human skeletal metastatic cell lines directly degrade bone matrix using matrix metalloproteinases. Br J Cancer 1998 (in press).
5. Alexandrow MG, Moses HL. Transforming growth factor β and cell cycle regulation Cancer Res 1995; 55: 1452-7.
6. Ignotz RA, Endo T, Massagué J. Regulation of fibronectin and type I collagen mRNA levels by transforming growth factor β. J Biol Chem 1987; 262: 6443-6.
7. Ignotz RA, Massagué J. Transforming growth factor β stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J Biol Chem 1986; 261: 4337-45.
8. Franzèn P, Ichijo H, Miyazono K. Different signals mediate transforming growth factor β1-induced growth inhibition and extracellular matrix production in prostatic carcinoma cells. Exp Cell Res 1993; 207: 1-7.
9. Mulder KM, Ramey MK, Hoosein NM et al. Characterization of transforming growth factor-β-resistant subclones isolated from a transforming growth factor-β-sensitive human colon carcinoma cell line. Cancer Res 1988; 48: 7120-5.
10. Heino J, Massagué J. Transforming growth factor-β switches the pattern of integrins expressed in MG-63 human osteosarcoma cells and causes a selective loss of cell adhesion to laminin. J Biol Chem 1989; 264: 21806-11.
11. Matrisian LM. Matrix metalloproteinase gene expression. Ann NY Acad Sci 1994; 732: 42-50.
12. Huhtala P, Tuuttila A, Chow LT et al. Complete structure of the human gene for the 92-kDa type IV collagenase. Divergent regulation of expression for the 92- and 72-kilodalton enzyme genes in HT-2080 cells. J Biol Chem 1991; 266: 16485-90.
13. Arnoletti JP, Albo D, Granick MS et al. Thrombospondin and transforming growth factor-beta I increase expression of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in human MDA-MB-231 breast cancer cells. Cancer 1995; 76: 998-1005.
14. Edwards DR, Leco KJ, Beaudry PP et al. Differential effects of transforming growth factor-beta1 on the expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in young and old human fibroblasts. Exp Gerontol 1996; 31: 207-23.
15. Overall CM. Regulation of tissue inhibitors of matrix metalloproteinase expression. Ann NY Acad Sci 1994; 732: 51-64.
16. Rydziel S, Varghese S, Canalis E. Transforming growth factor beta1 inhibits collagenase 3 expression by transcriptional and post-transcriptional mechanisms in osteoblast cultures. J Cell Physiol 1997; 170: 145-52.
17. Sehgal I, Baley PA, Thompson TC. Transforming growth factor β1 stimulates contrasting responses in metastatic versus primary mouse prostate cancer-derived cell lines in vitro. Cancer Res 1996; 56: 3359-65.
18. Benbow U, Brinckerhoff CE. The AP-I site and MMP gene regulation: what is all the fuss about? Matrix Biol 1997; 15: 519-26.
19. Kerr LD, Miller DB, Matrisian LM. TGF-β1 inhibition of transin/stromelysin gene expression is mediated through a Fos binding sequence. Cell 1990; 51: 267-78.
20. Overall CM, Wrana JL, Sodek J. Transcriptional and post-transcriptional regulation of 72-kDa gelatinase/type IV collagenase by transforming growth factor-β1 in human fibroblasts. J Biol Chem 1991; 266: 14064-71.
21. Bonewald LF, Mundy GR. Role of transforming growth factor-beta in bone remodeling. Clin Orthop Rel Res 1990; 250: 261-76.
22. Knabbe C, Lippman ME, Wakefield LM et al. Evidence that transforming growth factor-β is hormonally regulated negative growth factor in human breast cancer cells. Cell 1987; 48: 417-28.
23. Cailleau R, Young R, Olive M, Reeves Jr. WJ. Breast tumor cell lines from pleural effusions. J Natl Cancer Inst 1974; 53: 661-74.
24. Mbalaviele G, Dunstan CR, Sasaki A et al. E-Cadherin expression in human breast cancer cells suppresses the development of osteolytic bone metastases in an experimental metastasis model. Cancer Res 1996; 56: 4063-70.
25. Kaighn ME, Narayan KS, Ohnuki Y et al. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 1979; 17: 16-23.
26. Shervrin DH, Kukreja SC, Ghosh L, Lad TE. Development of skeletal metastasis by human prostate cancer in athymic nude mice. Clin Expl Metastasis 1988; 6: 401-9.
27. Smith HS. In vitro properties of epithelial cell lines established from human carcinomas and nonmalignant tissue. J Natl Cancer Inst 1979; 62: 225-30.
28. Owens RB, Smith HS, Nelson-Rees WA, Springer EL. Epithelial cell cultures from normal and cancerous human tissues. J Natl Cancer Inst 1976; 56: 843-9.
29. Rodan SB, Imai Y, Thiede MA et al. Characterization of a human osteosarcoma cell line (Saos-2) with osteoblastic properties. Cancer Res 1987; 47: 4961-6.
30. Heussen C, Dowdle EB. Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates. Anal Biochem 1980; 102: 196-202.
31. Oliver GW, Leferson JD, Stetler-Stevenson WG, Kleiner DE. Quantitative reverse zymography: analysis of picogram amounts of metalloproteinase inhibitors using gelatinase A and B reverse zymograms. Anal Biochem 1997; 244: 161-6.
32. Rago R, Mitchen J, Wilding G. DNA fluorometric assay in 96-well tissue culture plates using Hoechst 33258 after cell lysis by freezing in distilled water. Anal Bioehem 1990; 191: 31-4.
33. Liotta LA, Tryggvason K, Garbisa S et al. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 1980; 284: 67-8.
34. Tarin D, Hoyt BJ, Evans DJ. Correlation of collagenase secretion with metastatic-colonization potential in naturally occurring murine mammary tumors. Br J Cancer 1982; 46: 266-78.
35. Turpeenniemi-Hujanen T, Thorgeirsson UP, Hart IR et al. Expression of collagenase IV (basement membrane collagenase) activity in murine tumor cell hybrids that differ in metastatic potential. J Natl Cancer Inst 1985; 75: 99-103.
36. Nakaijama M, Welch DR, Belloni PN, Nicolson GL. Degradation of basement membrane type IV collagen and lung subendothelial matrix by rat mammary adenocarcinoma cell clones of differing metastatic potentials. Cancer Res 1987; 47: 4869-76.
37. Sreenath T, Matrisian LM, Stetler-Stevenson W et al. Expression of matrix metalloproteinase genes in transformed rat cell lines of high and low metastatic potential. Cancer Res 1992; 52: 4942-7.
38. Carrington JL, Roberts AB, Flanders KC et al. Accumulation, localization, and compartmentation of transforming growth factor β during endochondral bone development. J Cell Biol 1988; 107: 1969-75.
39. Shimizu S, Nishikawa Y, Kuroda K et al. Involvement of transforming growth factor β1 in autocrine enhancement of gelatinase B secretion by murine metastatic colon carcinoma cells. Cancer Res 1996; 56: 3366-70.
40. Nagase H, Ogata Y, Suzuki K et al. Substrate specificities and activation mechanisms of matrix metalloproteinases. Biochem Soc Trans 1991; 19: 715-8.
41. Mundy GR, Yoneda T. Facilitation and suppression of bone metastasis. Clin Orthop Rel Res 1995; 312: 34-44.
42. Lipton A. Bisphosphonates and breast carcinoma. Cancer 1997; 80: 1668-73.
43. Brown PD, Levy AT, Margulies IMK et al. Independent expression and cellular processing of Mr 72,000 type IV collagenase and interstitial collagenase in human tumorigenic cell lines. Cancer Res 1990; 50: 6184-91.
44. Lokeshwar BL, Selzer MG, Block NL, Gunja-Smith Z. Secretion of matrix metalloproteinases and their inhibitors (tissue inhibitor of metalloproteinases) by human prostate in explant cultures: reduced tissue inhibitor of metalloproteinase secretion by malignant tissues. Cancer Res 1993; 53: 4493-8.
45. Kalkhoven E, Roelen BAJ, de Winter JP et al. Resistance to transforming growth factor β and activin due to reduced receptor expression in human breast tumor cell lines. Cell Growth Diff 1995; 6: 1151-61.
46. Valverius EM, Walker-Jones D, Bates SE et al. Production of and responsiveness to transforming growth factor-β in normal and oncogene-transformed human mammary epithelial cells. Cancer Res 1989; 49: 6269-74.
47. Jeng M-H, ten Dijke P, Iwata KK, Jordan VC. Regulation of the levels of three transforming growth factor β mRNAs by estrogen and their effects on the proliferation of human breast cancer cells. Mol Cell Endocrinol 1995; 97: 115-23.
48. Koli KM, Arteaga CL. Predominant cytosolic localization of type II transforming growth factor β receptors in human breast carcinoma cells. Cancer Res 1997; 57: 970-7.
49. Takeuchi Y, Fukumoto S, Matsumoto T. Relationship between actions of transforming growth factor (TGF)-β and cell surface expression of its receptors in clonal osteoblastic cells. J Cell Physiol 1995; 162: 315-21.
50. Aimes RT, Quigley JP. Matrix metalloproteinase-2 is an interstitial collagenase. J Biol Chem 1995; 5872-6.
51. Woessner Jr. JF. The family of matrix metalloproteinases. Ann NY Acad Sci 1994; 732: 11-21.